RHYTHM PHARMACEUTICALS, INC. Assets, Fair Value Disclosure
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Assets, Fair Value Disclosure of $315.01 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:AssetsFairValueDisclosure · last filed 2026-08-04
- 2026-06-30: Assets, Fair Value Disclosure $315.01M.
- 2026-03-31: Assets, Fair Value Disclosure $326.73M.
- 2025-12-31: Assets, Fair Value Disclosure $369.78M.
- 2024-12-31: Assets, Fair Value Disclosure $306.02M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $315.01M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $326.73M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $369.78M 10-Q · filed 2026-08-04 |
| 2024-12-31 | $306.02M 10-K · filed 2026-02-26 |
| 2020-09-30 | $134.11M 10-Q · filed 2020-11-02 |
| 2020-06-30 | $169.53M 10-Q · filed 2020-08-03 |
| 2020-03-31 | $201.65M 10-Q · filed 2020-05-04 |
| 2019-12-31 | $230.16M 10-Q · filed 2020-11-02 |
| 2019-09-30 | $90.75M 10-Q · filed 2019-11-01 |
| 2019-06-30 | $132.05M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $179.50M 10-Q · filed 2019-05-03 |
| 2018-12-31 | $202.52M 10-K · filed 2020-03-02 |
| 2017-12-31 | $113.85M 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |